Study summary

Adding orelabrutinib to first-line chemotherapy gave complete responses in most patients

R-MO trial (orelabrutinib) · 37 people, phase 2 · Published April 2025, Blood Cancer Journal

87.1%complete response after induction

What was tested

Rituximab and high-dose methotrexate with orelabrutinib, a BTK inhibitor, for newly diagnosed PCNSL.

What they found

What it means

Led to randomized trials of BTK inhibitors in first-line treatment.

Blood Cancer J, via PubMed ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.